The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Targeting survivin in cancer therapy
Abstract
BACKGROUND: Survivin is a structurally unique member of the inhibitor of apoptosis protein (IAP) family that acts as a suppressor of apoptosis and plays a central role in cell division. Owing to its massive upregulation in human tumors and its involvement in cancer progression and treatment resistance, survivin is currently undergoing extensive investigation as a novel therapeutic target. OBJECTIVE: The purpose of this review is to define the potential of survivin as a therapeutic target for new anticancer interventions. METHODS: The literature dealing with the therapeutic targeting of survivin has been carefully reviewed. RESULTS/CONCLUSION: Several preclinical studies have demonstrated that downregulation of survivin expression or function, accomplished by means of various strategies, reduced tumor growth potential, increased the apoptotic rate and sensitized tumor cells to chemotherapeutic drugs and radiation in different human tumor models. Moreover, the first survivin inhibitors are being currently evaluated in clinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family
Eckelman, B. P., Salvesen, G. S., & Scott, F. L. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400795 · Cited by 813
The inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565
Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563
Cited by
Survivin: A new target for anti-cancer therapy
Ryan, B. M., O’Donovan, N., & Duffy, M. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.05.003 · Cited by 379
Survivin: A molecular biomarker in cancer
Mittal, R., Jaiswal, P., & Goel, A. (2015) · Indian Journal of Medical Research · doi:10.4103/0971-5916.159250 · Cited by 352
Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Metadata
- Authors
- Pennati, M., Folini, M., & Zaffaroni, N.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa Healthcare
- Published
- 2008-03-18
- Volume
- 12
- Issue
- 4
- Pages
- 463-476
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2031056725
- Cited by
- 180
- References
- 3
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting survivin in cancer therapy. https://app.cochat.ai/papers/10.1517/14728222.12.4.463
- The paper
- Pennati, M., Folini, M., & Zaffaroni, N. (2008). Targeting survivin in cancer therapy. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.12.4.463
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.